{
    "nct_id": "NCT05985681",
    "official_title": "A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, A Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer",
    "inclusion_criteria": "* Women, age 18 - 45 years. Because no dosing or adverse event (AE) data is currently available for the use of RG1-VLP in humans, children and adolescents are excluded from this study\n* White blood cell (WBC) between 3000/mm^3 - institutional upper limit of normal\n* Hemoglobin (Hgb) between 10 g/dl - institutional upper limit of normal\n* Platelets >= 100,000/mm^3\n* Serum creatinine within institutional normal limits\n* Bilirubin =< 2x institutional upper limit of normal\n* Alanine aminotransferase (ALT) =< 2x institutional upper limit of normal\n* Aspartate aminotransferase (AST) =< 2x institutional upper limit of normal\n* Human immunodeficiency virus (HIV)-1/HIV-2 negative\n* Hepatitis B and hepatitis C negative\n* The effects of RG1-VLP vaccination on the developing human fetus at the proposed doses are unknown. For this reason, all women of childbearing potential will have a pregnancy test and all heterosexually active women must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately\n* The following persons are not considered to be able to bear children and are therefore eligible to participate without the use of concurrent birth control:\n\n  * Female with bilateral oophorectomy and/or hysterectomy\n  * Female with fallopian tubes cut, tied or sealed\n  * Female with sterilization implant (e.g. Adiana, Essure) placed > 3 months prior to randomization\n  * Female post-menopausal (> 1 year since last menses or prior laboratory follicle stimulating hormone [FSH] value per institutional range indicating post-menopausal)\n* Eastern Cooperative Oncology Group (ECOG) performance status of =< 1\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 45 Years",
    "exclusion_criteria": "* History of any of the following:\n\n  * Prior or current genital warts\n  * For women 25 and older: any abnormal Pap smear and positive HPV deoxyribonucleic acid (DNA) test (if co-testing), or positive HPV DNA test (if primary HPV screening)\n  * Treatment for anogenital intraepithelial neoplasia (cervical intraepithelial neoplasia [CIN], anal intraepithelial neoplasia [AIN], vaginal intraepithelial neoplasia [VAIN], vulvar intraepithelial neoplasia [VIN])\n  * Treatment for any cancer\n* History of anaphylaxis to vaccines or fever > 100 degrees Fahrenheit (F) within 72 hours of vaccination\n* Any prior vaccination with Gardasil, Gardasil-9, or Cervarix or other HPV vaccine\n* Receipt of blood products within 3 months of enrollment, or continuing plasma donation\n* Participants receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the adjuvant or to RG1-VLP\n* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant women or actively lactating women are excluded from this study because RG1-VLP is a vaccine with the potential for teratogenic or abortifacient effects\n* Planned receipt of any inactivated vaccine in the 2 weeks preceding and the 2 weeks following any trial vaccination\n* Planned receipt of any live attenuated vaccine in the 4 weeks preceding and the 4 weeks following any trial vaccination\n* Women with a history of bleeding disorders or use of anticoagulants (aspirin is acceptable)\n* Had prior medical conditions:\n\n  * Rheumatoid arthritis or other auto-immune disease\n  * Congenital or acquired immunodeficiency\n  * Collagen vascular disease\n* Following medical treatments:\n\n  * Current use of immunosuppressive drugs including corticosteroid use (inhaled or topical steroids are permitted)",
    "miscellaneous_criteria": ""
}